

§ 600.81

adverse experience reports are not releasable to the public under FDA's public information regulations in part 20 of this chapter. For vaccine adverse experience reports, these data will become part of the CDC Privacy Act System 09-20-0136, "Epidemiologic Studies and Surveillance of Disease Problems." Information identifying the person who received the vaccine or that person's legal representative will not be made available to the public, but may be available to the vaccinee or legal representative.

(i) *Recordkeeping.* The licensed manufacturer shall maintain for a period of 10 years records of all adverse experiences known to the licensed manufacturer, including raw data and any correspondence relating to the adverse experiences.

(j) *Revocation of biologics license.* If a licensed manufacturer fails to establish and maintain records and make reports required under this section with respect to a licensed biological product, FDA may revoke the biologics license for such a product in accordance with the procedures of § 601.5 of this chapter.

(k) *Exemptions.* Manufacturers of the following listed products are not required to submit adverse experience reports under this section:

(1) Whole blood or components of whole blood.

(2) In vitro diagnostic products, including assay systems for the detection of antibodies or antigens to retroviruses. These products are subject to the reporting requirements for devices.

(l) *Disclaimer.* A report or information submitted by a licensed manufacturer under this section (and any release by FDA of that report or information) does not necessarily reflect a conclusion by the licensed manufacturer or FDA that the report or information constitutes an admission that the biological product caused or contributed to an adverse effect. A licensed manufacturer need not admit, and may deny, that the report or information submitted under this section constitutes an admission that the biological product caused or contributed to an adverse effect. For purposes of this provision, this paragraph also includes any person

21 CFR Ch. I (4-1-03 Edition)

reporting under paragraph (c)(1)(iii) of this section.

[59 FR 54042, Oct. 27, 1994, as amended at 62 FR 34168, June 25, 1997; 62 FR 52252, Oct. 7, 1997; 63 FR 14612, Mar. 26, 1998; 64 FR 56449, Oct. 20, 1999]

§ 600.81 Distribution reports.

The licensed manufacturer shall submit information about the quantity of the product distributed under the biologics license, including the quantity distributed to distributors. The interval between distribution reports shall be 6 months. Upon written notice, FDA may require that the licensed manufacturer submit distribution reports under this section at times other than every 6 months. The distribution report shall consist of the bulk lot number (from which the final container was filled), the fill lot numbers for the total number of dosage units of each strength or potency distributed (e.g., fifty thousand per 10-milliliter vials), the label lot number (if different from fill lot number), labeled date of expiration, number of doses in fill lot/label lot, date of release of fill lot/label lot for distribution at that time. If any significant amount of a fill lot/label lot is returned, include this information. Disclosure of financial or pricing data is not required. As needed, FDA may require submission of more detailed product distribution information. Upon written notice, FDA may require that the licensed manufacturer submit reports under this section at times other than those stated. Requests by a licensed manufacturer to submit reports at times other than those stated should be made as a request for a waiver under § 600.90.

[59 FR 54042, Oct. 27, 1994, as amended at 64 FR 56449, Oct. 20, 1999]

§ 600.90 Waivers.

(a) A licensed manufacturer may ask the Food and Drug Administration to waive under this section any requirement that applies to the licensed manufacturer under §§ 600.80 and 600.81. A waiver request under this section is required to be submitted with supporting documentation. The waiver request is required to contain one of the following:

(1) An explanation why the licensed manufacturer's compliance with the requirement is unnecessary or cannot be achieved,

(2) A description of an alternative submission that satisfies the purpose of the requirement, or

(3) Other information justifying a waiver.

(b) FDA may grant a waiver if it finds one of the following:

(1) The licensed manufacturer's compliance with the requirement is unnecessary or cannot be achieved,

(2) The licensed manufacturer's alternative submission satisfies the requirement, or

(3) The licensed manufacturer's submission otherwise justifies a waiver.

PART 601—LICENSING

Subpart A—General Provisions

Sec.

601.2 Applications for biologics licenses; procedures for filing.

601.4 Issuance and denial of license.

601.5 Revocation of license.

601.6 Suspension of license.

601.7 Procedure for hearings.

601.8 Publication of revocation.

601.9 Licenses; reissuance.

Subpart B [Reserved]

Subpart C—Biologics Licensing

601.12 Changes to an approved application.

601.15 Foreign establishments and products; Samples for each importation.

601.20 Biologics licenses; issuance and conditions.

601.21 Products under development.

601.22 Products in short supply; initial manufacturing at other than licensed location.

601.25 Review procedures to determine that licensed biological products are safe, effective, and not misbranded under prescribed, recommended, or suggested conditions of use.

601.26 Reclassification procedures to determine that licensed biological products are safe, effective, and not misbranded under prescribed, recommended, or suggested conditions of use.

601.27 Pediatric studies.

601.28 Annual reports of postmarketing pediatric studies.

601.29 Guidance documents.

Subpart D—Diagnostic Radiopharmaceuticals

601.30 Scope.

601.31 Definition.

601.32 General factors relevant to safety and effectiveness.

601.33 Indications.

601.34 Evaluation of effectiveness.

601.35 Evaluation of safety.

Subpart E—Accelerated Approval of Biological Products for Serious or Life-Threatening Illnesses

601.40 Scope.

601.41 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.

601.42 Approval with restrictions to assure safe use.

601.43 Withdrawal procedures.

601.44 Postmarketing safety reporting.

601.45 Promotional materials.

601.46 Termination of requirements.

Subpart F—Confidentiality of Information

601.50 Confidentiality of data and information in an investigational new drug notice for a biological product.

601.51 Confidentiality of data and information in applications for biologics licenses.

Subpart G—Postmarketing Studies

601.70 Annual progress reports of postmarketing studies.

Subpart H—Approval of Biological Products When Human Efficacy Studies Are Not Ethical or Feasible

601.90 Scope.

601.91 Approval based on evidence of effectiveness from studies in animals.

601.92 Withdrawal procedures.

601.93 Postmarketing safety reporting.

601.94 Promotional materials.

601.95 Termination of requirements.

AUTHORITY: 15 U.S.C. 1451–1561; 21 U.S.C. 321, 351, 352, 353, 355, 356b, 360, 360c–360f, 360h–360j, 371, 374, 379e, 381; 42 U.S.C. 216, 241, 262, 263, 264; sec 122, Pub. L. 105–115, 111 Stat. 2322 (21 U.S.C. 355 note).

SOURCE: 38 FR 32052, Nov. 20, 1973, unless otherwise noted.

CROSS REFERENCES: For U.S. Customs Service regulations relating to viruses, serums, and toxins, see 19 CFR 12.21–12.23. For U.S. Postal Service regulations relating to the admissibility to the United States mails see parts 124 and 125 of the Domestic Mail